Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $226 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $226.
August 07, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Jazz Pharmaceuticals and maintained a price target of $226.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $226 price target indicates a positive outlook for Jazz Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100